ALB and arthritic joint disease: After a single injection and subsequent sol–gel phase transition, the hydrogels are localized as a “drug-release depot”, from where the released CCPA can locally activate A1R to exert analgesic effects, the released TP@HSA NPs can enter the lymphatic and blood circulatory system, and then effectively target the arthritis joints via HSA’s targeting ability to suppress inflammation.